Jiang Z - Search Results

1

Analytical validation of the DropXpert S6 system for diagnosis of chronic myelocytic leukemia.

Wei W, Li S, Zhang Y, Deng S, He Q, Zhao X, Xu Y, Yu L, Ye J, Zhao W, Jiang Z. Wei W, et al. Among authors: jiang z. Lab Chip. 2024 Jun 11;24(12):3080-3092. doi: 10.1039/d4lc00175c. Lab Chip. 2024. PMID: 38747247

2

Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics.

Jiang ZP, Wang YR, Xu P, Liu RR, Zhao XL, Chen FP. Jiang ZP, et al. Basic Clin Pharmacol Toxicol. 2008 Nov;103(5):433-44. doi: 10.1111/j.1742-7843.2008.00300.x. Epub 2008 Sep 17. Basic Clin Pharmacol Toxicol. 2008. PMID: 18801030 Free article.

3

Correlation between MDR1 methylation status in the promoter region and MDR1 genetic polymorphism in 194 healthy Chinese Han subjects.

Jiang ZP, Xu P, Liu RR, Li HD, Wang GP, Zhao XL, Chen FP. Jiang ZP, et al. Pharmacogenomics. 2008 Dec;9(12):1801-8. doi: 10.2217/14622416.9.12.1801. Pharmacogenomics. 2008. PMID: 19072639

4

Hypothesizing that histone deacetylase inhibitors can be used to reverse multiple drug resistance.

Jiang ZP, Xu P, Wang GP, Zhao XL, Chen FP. Jiang ZP, et al. Med Hypotheses. 2010 Jan;74(1):92-4. doi: 10.1016/j.mehy.2009.07.036. Epub 2009 Aug 22. Med Hypotheses. 2010. PMID: 19700246

5

Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.

Jiang ZP, Zhao XL, Takahashi N, Angelini S, Dubashi B, Sun L, Xu P. Jiang ZP, et al. Pharmacogenomics. 2017 Jan;18(1):35-56. doi: 10.2217/pgs-2016-0103. Epub 2016 Dec 19. Pharmacogenomics. 2017. PMID: 27991849

6

Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.

Wang Q, Jiang ZP, Yu EQ, Zeng J, Zhu Y, Cai HL, Yan M, Xiang DX, Zhao XL, Xu P, Jiao Z, Banh HL. Wang Q, et al. Among authors: jiang zp. Pharmacogenomics. 2019 Mar;20(4):251-260. doi: 10.2217/pgs-2018-0139. Epub 2019 Feb 15. Pharmacogenomics. 2019. PMID: 30767712

7

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.

Wang Q, Jiang ZP, Zeng J, Zhu Y, Cai HL, Xiang DX, He Q, Shi XL, Zhong AN, Zhao XL, Xu P. Wang Q, et al. J Pharm Pharm Sci. 2020;23(1):1-9. doi: 10.18433/jpps30559. J Pharm Pharm Sci. 2020. PMID: 32027818 Free article. Clinical Trial.

8

Down-regulating NQO1 promotes cellular proliferation in K562 cells via elevating DNA synthesis.

Xiao FY, Jiang ZP, Yuan F, Zhou FJ, Kuang W, Zhou G, Chen XP, Liu R, Zhou HH, Zhao XL, Cao S. Xiao FY, et al. Life Sci. 2020 May 1;248:117467. doi: 10.1016/j.lfs.2020.117467. Epub 2020 Feb 24. Life Sci. 2020. PMID: 32105706 Free article.

9

Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.

Cheng C, Yuan F, Chen XP, Zhang W, Zhao XL, Jiang ZP, Zhou HH, Zhou G, Cao S. Cheng C, et al. Biomed Pharmacother. 2021 Oct;142:111652. doi: 10.1016/j.biopha.2021.111652. Epub 2021 Jun 8. Biomed Pharmacother. 2021. PMID: 34112534 Free article.

10

CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML.

Zhong AN, Yin Y, Tang BJ, Chen L, Shen HW, Tan ZP, Li WQ, He Q, Sun B, Zhu Y, Xiao J, Jiang ZP, Xu P. Zhong AN, et al. Front Pharmacol. 2021 Sep 13;12:728916. doi: 10.3389/fphar.2021.728916. eCollection 2021. Front Pharmacol. 2021. PMID: 34588984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19,470 results

Search Page

Filters